Industry News
Pharmaceutical Industry News

As part of the MFN drug pricing…
As part of the MFN drug pricing deal the Trump administration signed with obesity giants Eli Lilly and Novo Nordisk, Medicare recently launched a “bridge” model, offering weight loss drugs to eligible seniors at $50
After losing Bristol Myers Squibb…
After losing Bristol Myers Squibb as a client, Cellares continues to move forward with the right-sizing its CEO unveiled late last month.
TV outcomes company EDO determined…
TV outcomes company EDO determined that Galderma’s skin disease med Nemluvio led the charge with the highest engagement score across all advertisers during the 2025-26 NFL football season.
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
After pivoting from mobile gaming…
After pivoting from mobile gaming marketing to pharma, Genentech performance marketing engagement lead Tiffany William is making performance marketing "less daunting" and "more fun" and approachable.
Novartis appears to have broken…
Novartis appears to have broken the curse of the BTK inhibitor class. The Swiss pharma announced Tuesday that two phase 3 trials for Rhapsido in relapsing multiple sclerosis hit their goals without any liver safety
This podcast feature a fireside…
This podcast feature a fireside chat between Dr Ira Mellman, PICI and Dr Axel Hoos, Former CEO, Scorpion Therapeutics from the 2026 Immuno-Oncology 360° conference.
A new survey out from Bausch +…
A new survey out from Bausch + Lomb has shown that dry eye disease is one of the least recognized symptoms present in perimenopausal and postmenopausal women.
Emergent BioSolutions looks to…
Emergent BioSolutions looks to expand awareness and education of its Narcan opioid overdose reversal spray with an expanded campaign that kicked off on International Overdose Awareness Day.
Some four months after the White…
Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top players, the U.S. government is back for round 2, this time lining up
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
BioMarin now collects royalties on…
BioMarin now collects royalties on the more convenient competitor product. Ascendis will pay 20% of Yuviwel net sales in the U.S. dating back to the first commercial sales and through to May 2030.
Samanta Cimitan, Ph.D., will serve…
Samanta Cimitan, Ph.D., will serve in a newly created role as the CDMO's chief commercial officer, SVP and member of the extended executive committee starting Jan. 1, 2027.
The FDA sent Alar Pharmaceuticals…
The FDA sent Alar Pharmaceuticals an untitled letter after finding fault with the company’s exhibit booth display and brochure at a recent conference.
Jazz Pharmaceuticals has added a…
Jazz Pharmaceuticals has added a second overall survival win to Ziihera’s cap, bolstering the bispecific’s claim as the new HER2 agent of choice in stomach cancer.
Late August has been rough for IV…
Late August has been rough for IV solution makers as B. Braun added to its recall tally once more, building on Baxter’s three recalls of similar products in the same time frame.
After a surprise washout in a…
After a surprise washout in a recent phase 3 trial of AstraZeneca and Ionis’ antisense oligonucleotide Wainua, the likely reason for the miss is being laid bare, in a potential ill omen for others pursuing
Walmart to Pay $50 Million to Settle Opioid Lawsuit, US Says
The resolution is part of an effort to hold retailers and pharmacists accountable for what the government says were their roles in the opioid epidemic.
The FDA has approved Takeda’s…
The FDA has approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism to the nonmalignant rare blood cancer and handing CEO Julie Kim another major regulatory win since taking the helm.
The FDA has signed off on a label…
The FDA has signed off on a label expansion for PharmaEssentia's Besremi, endorsing it as a treatment for the rare bone marrow disorder essential thrombocythemia.


